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Objective: The presence of epidermal growth factor receptor
(EGFR) mutations has been reported to predict the response to
gefitinib in pulmonary adenocarcinoma patients. A retrospective
analysis was conducted to identify the correlation between com-
puted tomographic findings of the nodules and EGFR status.
Patients and Methods: Computed tomographic findings of 38
patients with peripheral pulmonary adenocarcinoma with EGFR
mutations were reviewed and compared with those of 42 peripheral
pulmonary adenocarcinoma patients with wild-type EGFR.
Results: Mutations were found significantly more frequently among
women (28 of 45 women versus 10 of 35 men) and among non-
smokers (31 of 47 non-smokers and 7 of 33 smokers). The L858R
mutation was found in 18 cases. Several types of deletion mutants in
exon 19 were found in 18 cases. The nodules with EGFR mutations
(2.5  1.0 cm) were significantly smaller in diameter than those in
the wild-type group (3.1  1.9 cm). Ground glass opacity (GGO)
was more often observed in the mutation group (28 of 38) than in the
wild-type group (24 of 42), but the difference was not statistically
significant. When mutations were analyzed with reference to both
the tumor size and GGO ratio, patients with a tumor 3 cm and a
GGO ratio 50% often had EGFR mutations, and most (10 of 12)
were expressed in female patients. No male adenocarcinoma patients
with a tumor larger than 4.0 cm had EGFR mutations.
Conclusions: EGFR mutations were found most frequently in small
peripheral adenocarcinomas with a GGO ratio 50%, especially
among women. These factors may be useful in deciding therapeutic
strategies for adenocarcinomas when resection or biopsy is not feasible.
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The incidence of adenocarcinoma of the lung has increaseddramatically during the past few decades in Japan.1 His-
tologically and biologically adenocarcinomas of the lung
constitute a heterogeneous group of tumors. Surgical resec-
tion is an optimal strategy to treat peripheral adenocarcino-
mas at an early stage.2 Chemotherapy is usually selected for
patients with advanced lung cancer, and many reports have
shown the prolongation of survival and improvement of
quality of life.3 However, the effect of conventional chemo-
therapy has been unsatisfactory, and the prognosis has been
poor. Gefitinib, a synthetic small molecule that inhibits epi-
dermal growth factor receptor (EGFR) tyrosine kinase, is
now being used for unresectable or recurrent non-small cell
lung cancer (NSCLC). Although the response rates have not
been high (9–19%) in advanced NSCLC,4,5 a group of pa-
tients showed dramatic responses to gefitinib. Recently two
groups reported that clinical responsiveness to gefitinib in
NSCLC correlated with somatic mutations in the kinase
domain of EGFR gene.6,7 These EGFR mutations have been
observed frequently among the Japanese,8 women, non-
smokers, patients with adenocarcinoma,5,9,10 and especially
patients with the bronchio-alveolar pathologic subtype.10 The
presence of EGFR mutations has been a good predictor of
gefitinib effectiveness. Many types of EGFR mutations have
been reported. Deletion mutation in exon 18 and point mu-
tation of L858R in exon 21 are representative components,
and they occupied approximately 90% of the mutations.6,8
The EGFR mutations are usually assessed by direct sequenc-
ing of DNA samples from resected lung cancers.6,7 However,
small carcinoma specimens from biopsies are often not suit-
able for sequencing. If the mutation status can be predicted by
computed tomographic (CT) findings, it will be beneficial for
patients with unresectable lung cancer and those who do not
wish to undergo surgery or biopsy. In this study, we sought to
determine whether there was a correlation between the find-
ings of CT in peripheral adenocarcinomas and EGFR muta-
tion status and differences of mutations.
PATIENTS AND METHODS
Patients
There were 338 patients with lung cancer who under-
went surgical resection at Nagoya City University Hospital
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from January 2000 to December 2004. These 338 patients
with lung carcinomas included 196 adenocarcinomas. Of
these, 135 resected samples were available for the analysis of
EGFR mutation status. We identified 57 patients with an
EGFR mutation. Adenocarcinomas located in the hilum or
with visible atelectasis on CT were excluded. We selected 38
patients with thin-sliced CT findings as a study group. We
identified 78 patients with wild-type EGFR status among
patients who underwent surgery from January 2000 to De-
cember 2004. Of these 78 patients, 42 patients who under-
went surgery from January 2003 to December 2004 were
selected as controls. These 42 patients also had a tumor
located in the peripheral area without large lobar atelectasis
that hid radiological characteristics of tumors. Age, gender,
and smoking history were not matched between the two study
groups because of the potential for influencing EGFR muta-
tion status. There were 45 women and 35 men whose ages
ranged from 40 to 86 years (median, 66 years). Diagnosis of
adenocarcinoma was confirmed histologically by hematoxy-
lin and eosin staining by the pathologists in our hospital.
CT Findings
We retrospectively reviewed CT findings of 80 patients
with peripheral pulmonary adenocarcinoma. Conventional
CT images were obtained serially with 7- to 10-mm section
thickness, 7- to 10-mm section spacing, and high-resolution
images targeted to the tumor were obtained serially with 1- to
2-mm section thickness and 1- to 2-mm section spacing. All
CT images were reviewed by two radiologists who special-
ized in lung cancer and had not been informed of EGFR gene
mutation status. Ground glass opacity (GGO) was defined as
a hazy increase in lung attenuation without obscuring the
underlying bronchial or vascular structures. Area in the tumor
with GGO was defined as the GGO ratio and ranged from 0%
(pure solid) to 100% (pure GGO). In the partially solid
nodules, GGO ratio was determined by the two radiologists
using three-dimensionally reconstructed images. When their
decisions were not matched, the average of ratios was ac-
cepted. This GGO ratio was entirely subjective for the radi-
ologists. In addition, the presence of obvious pleural inden-
tations or concave, spicula, loblation, or notch, and vascular
convergences were assessed.
EGFR Mutation Analysis
In an earlier study, we found that the TaqMan poly-
merase chain reaction (PCR) assay was a rapid and sensitive
method for detecting EGFR mutations.11 The detailed proce-
dures of the TaqMan PCR assay have been described previ-
ously. The genomic DNA from tumor tissues was extracted
using the Wizard SV Genomic DNA Purification System
(Promega, Madison, WI) according to the manufacturer’s
instructions. The allele-specific primers and ABI PRISM
TaqMan MGB probes were designed with Primer Express 2.0
software (Applied Biosystems, Foster City, CA). TaqMan
PCR and genotyping analysis were performed on Applied
Biosystems 7500 Real Time PCR System (Applied Biosys-
tems) according to the manufacturer’s instructions. The reac-
tion mixtures were amplified in 1 L of genomic DNA (10
ng/L) or 1 L of 100-fold diluted PCR products, 5 L of 2x
TaqMan Universal Master Mix (Applied Biosystems), 0.5 L
of 20x primer/probe mix (each final concentration of primer
and probe is 9 M and 2 M), 3.5 L of ddH2O in a volume
of 10 L. PCR cycling conditions were as follows: one cycle
at 95°C for 10 min and 40 cycles at 95°C for 15 sec and 58°C
for 1 min. The results were analyzed on Applied Biosystems
7500 Real Time PCR System (Applied Biosystems) using an
allelic discrimination assay program.
Statistical Analysis
The unpaired t test was used for comparison of the
averages, and the 2 test or Fisher’s exact test was used for
comparisons of proportions. Differences were considered
significant when the P value was less than 0.05.
RESULTS
Patients and EGFR Mutation
The 80 patients’ ages ranged from 40 to 86 years old,
and the average age was not different between patients with
(66 years) or without (65 years) mutation. EGFR mutations
were found significantly more frequently among women (28
of 45) than among men (10 of 35) (P  0.003) (Table 1).
Smoking history was found significantly more frequently
among patients with wild-type EGFR (smoking history /:
26/16) than among patients with EGFR mutation (smoking
history /: 7/31) (Table 1) (P  0.0002). There were no
differences in pathological stage of tumors among the 80
patients in both groups (Table 1).
There were many types of mutations as reported pre-
viously.6,8 A point mutation of L858R in exon 21 was found
in 18 cases. Several types of deletion mutants in exon 19 were
found in these 18 cases (Del1a: 12, Del1b: 1, Del3: 2, Del4:
3). Another mutant type (L861Q) was found in two cases.
EGFR Mutation and CT Findings
The maximal diameter of the nodules and the presence
of GGO, pleural indentation, or concave, spicula, loblation,
or notch, vascular convergence were evaluated, and the cor-
TABLE 1. Clinicopathological data of 80 peripheral
adenocarcinomas
Wild-type (n  42) Mutation (n  38)
Median age (yr) 65 (40-80) 66 (40-86)
Gender*
Male
Female
25
17
10
28
Smoking history†
Yes
No
26
16
7
31
Pathological stage
IA
IB
IIA
IIB
IIIA
21
13
1
3
4
21
9
2
1
5
Max diameter (cm)‡ 3.1  1.9 (0.7-7.2) 2.5  0.9 (0.9-5.5)
* P  0.003. † P  0.0002. ‡ P  0.04.
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relation between the presence of radiological findings and
mutations was assessed (Table 2). The maximal diameters of
the nodules were 0.7 to 7.2 cm (3.1  1.9 cm) in the
wild-type group and 0.9 to 5.5 cm (2.5  1.0 cm) in the
mutation group (Table 1). The nodule diameters in the mu-
tation group were significantly smaller than those in the
wild-type group (P  0.04). There was no correlation be-
tween the presence of mutation and other CT findings, in-
cluding the presence of specula (/: 29/13 with wild-type,
27/11 with mutation), notch or loblation (/: 19/23 with
wild-type, 18/20 with mutation), pleural indentation or con-
cave (/: 24/18 with wild-type, 27/11 with mutation), and
vascular convergence (/: 38/4 with wild-type, 34/4 with
mutation) (Table 2). GGO was more often observed in the
mutation group (28 of 38) than in the wild-type group (24 of
42), although this trend was not statistically significant (P 
0.12). We next analyzed the EGFR mutation in relation to the
diameter of nodules and the GGO ratio (Figure 1). Patients
with a GGO ratio 50% with a tumor size 3 cm (shaded
area in Figure. 1) included 12 mutations and 5 wild types,
which was significantly more frequent than that seen for
patients with a GGO ratio of 50% with a tumor 3cm in
diameter (dotted area in Figure 1), or with a tumor 3 cm in
diameter (unmarked area in Figure 1). When gender was
considered, female patients with a tumor 3 cm and a GGO
ratio 50% had the highest frequency of EGFR mutations
(10 of 12) (Figure 2). It was not significant only in women
(P  0.11) because the number of patients became smaller.
Among male patients with a tumor3.0 cm, wild-type EGFR
was often seen (9 of 12), and GGO features were recessive
(Figure 3). None had EGFR mutation in a tumor 4.0 cm.
Figure 4 shows the distribution of mutation types (L858R and
deletion types) according to the diameter and GGO ratios.
Most patients with L858R had tumors 3 cm. The patients
with deletion type of mutants were more or less evenly
distributed.
DISCUSSION
The mechanisms that underlie the generation of adeno-
carcinomas of the lung are still unclear. According to recent
findings, EGFR mutations were more often seen in adenocar-
cinomas, particularly among female patients and
Asians.5,6,12,13 This suggests the importance of EGFR muta-
tions in adenocarcinomas in these patients. More importantly,
EGFR mutations seem to be related to the patient’s response
to gefitinib, a molecularly targeted drug against the tyrosine
kinase of EGFR.
Recently, the CT findings of peripheral adenocarcino-
mas have been investigated, especially in their early stag-
es.14,15 The presence and extent of GGO findings have been
suggested as prognostic factors.15 In the present study, we
analyzed the CT findings of patients with adenocarcinoma to
identify factors that may predict the presence of EGFR
mutations and thus the response to gefitinib. The maximal
diameter of nodules in the mutation group was significantly
smaller than that in the wild-type group. Furthermore, among
patients with a tumor diameter 3 cm and with a GGO ratio
50%, EGFR mutations were found more frequently than in
the other groups. Among women, 83% of patients with this
phenotype had EGFR mutations. Among male patients, most
with a large-diameter tumor (4.0 cm) had no or a low ratio
of GGO feature and a low possibility of EGFR mutations. It
is well known that gender influences the incidence of EGFR
mutations. Interestingly, gender may also influence the cor-
TABLE 2. CT findings and EGFR gene mutation
Wild-type Mutation Significance
Spicula
Spicula
29
13
27
11
NS
(P  0.85)
Notch
Notch
19
23
18
20
NS
(P  0.85)
Pleural indentation
Pleural indentation
24
18
27
11
NS
(P  0.20)
Vascular convergence
Vascular convergence
38
4
34
4
NS
(P  0.88)
GGO
GGO
24
18
28
10
NS
(P  0.12)
GGO, ground glass opacity; NS, not significant.
FIGURE 1. Maximal diameter, GGO occupied ratio, and
the presence of mutation. , wild-type EGFR gene. ●, muta-
tion of EGFR gene. In the shaded area with a GGO ratio of
50% with a tumor size 3 cm, patients with EGFR muta-
tions were seen more frequently compared with patients in
the dotted or the unmarked area with a GGO ratio of 50%
with a tumor 3 cm in diameter.
FIGURE 2. Maximal diameter, GGO occupied ratio, and
the presence of mutation among women. , wild-type EGFR
gene. ●, mutation of EGFR gene. The highest frequency (10
of 12) of EGFR mutations as defined by a GGO ratio of
50% with a tumor size 3 cm was seen in the shaded
area.
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relation between tumor diameters and GGO. Sex-dependent
features of a tumor may be present, which may reflect the
different mechanism of oncogenesis between the sexes.
In our recent study,16 L858R mutations were frequently
seen in the bronchio-alveolar pattern of adenocarcinomas.
Few reports have stated that the types of EGFR gene mutation
influenced characters of nodules, including the sensitivity for
gefitinib.13,17 Mitsudimi et al.17 reported gefitinib sensitivity
according to differences of EGFR mutations in their discus-
sion. Gefitinib was more effective among patients with a
deletion in exon 19. Moriguchi et al.18 reported a close
correlation of L858R mutation and no smoking history. Chou
et al.13 reported that patients with mutations in exon 20 had a
poorer gefitinib response. In the present study, most patients
with L858R had small-diameter tumors (3 cm), and the
patients with deletion-type mutations had tumors of various
diameters.
The present study was retrospective, and the number of
patients was not large enough to allow us to draw conclu-
sions. Further prospective study and accumulation of cases
are necessary.
In conclusion, small peripheral adenocarcinomas with a
high ratio of GGO components may predict the presence of
EGFR mutations, especially among female patients. Large
adenocarcinomas with low ratios of GGO may predict the
presence of wild-type EGFR among male patients. This
information may be useful in choosing therapeutic strategies
for lung adenocarcinomas when surgical resection or lung
biopsy is not feasible.
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FIGURE 3. Maximal diameter, GGO occupied ratio and the
presence of mutation among men. , wild-type EGFR gene.
●, mutation of EGFR gene. In the unmarked area with a tu-
mor 4.0 cm, none had EGFR mutation.
FIGURE 4. Maximal diameter, GGO occupied ratio, and
types of mutation. ●, deletion type of mutation in exon 19.
, L858R mutation. Most tumors of L858R mutation were
within 3 cm in a maximal diameter.
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